Summary
This phase 3 randomised controlled trial (IMvigor130) compared atezolizumab, a programmed death-ligand 1 inhibitor, combined with chemotherapy against placebo plus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma. The final overall survival analysis, published in The Lancet Oncology in 2023, presents long-term efficacy and safety outcomes from this international multi-centre study. The findings contribute to the evidence base for immunotherapy as a first-line treatment option in advanced urothelial cancer.
UK applicability
As a phase 3 international trial with multi-national participation, the results are directly applicable to UK oncology practice and NHS treatment pathways for advanced urothelial carcinoma. UK clinicians may use these findings to inform treatment decisions and patient counselling regarding first-line immunotherapy combinations.
Key measures
Overall survival; progression-free survival; treatment safety and adverse events
Outcomes reported
The study evaluated overall survival and safety outcomes in patients with untreated locally advanced or metastatic urothelial carcinoma treated with atezolizumab plus chemotherapy versus placebo plus chemotherapy. Final overall survival analysis results from this randomised phase 3 trial are reported.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.